Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
Martín-Algarra S, Espinosa E, Rubió J, López López JJ, Manzano JL, Carrión LA, Plazaola A, Tanovic A, Paz-Ares L. Martín-Algarra S, et al. Among authors: lopez lopez jj. Eur J Cancer. 2009 Mar;45(5):732-5. doi: 10.1016/j.ejca.2008.12.005. Epub 2009 Jan 29. Eur J Cancer. 2009. PMID: 19186051 Clinical Trial.
Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.
González-Larriba JL, Serrano S, Alvarez-Mon M, Camacho F, Casado MA, Díaz-Pérez JL, Díaz-Rubio E, Fosbrook L, Guillem V, López-López JJ, Moreno-Nogueira JA, Toribio J. González-Larriba JL, et al. Among authors: lopez lopez jj. Eur J Cancer. 2000 Dec;36(18):2344-52. doi: 10.1016/s0959-8049(00)00304-x. Eur J Cancer. 2000. PMID: 11094308 Clinical Trial.
Tumor markers at the time of recurrence in patients with germ cell tumors.
Trigo JM, Tabernero JM, Paz-Ares L, García-Llano JL, Mora J, Lianes P, Esteban E, Salazar R, López-López JJ, Cortés-Funes H. Trigo JM, et al. Among authors: lopez lopez jj. Cancer. 2000 Jan 1;88(1):162-8. doi: 10.1002/(sici)1097-0142(20000101)88:1<162::aid-cncr22>3.0.co;2-v. Cancer. 2000. PMID: 10618619
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G; European Cooperative Trial in Operable Breast Cancer Study Group. Gianni L, et al. Among authors: lopez lopez jj. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21. doi: 10.1158/1078-0432.CCR-05-0539. Clin Cancer Res. 2005. PMID: 16361558 Clinical Trial.
38 results